885101-89-3(GW9508)
885101-89-3(GW9508) 性质
| 熔点 | 90-92°C |
|---|---|
| 沸点 | 538.4±45.0 °C(Predicted) |
| 密度 | 1.222±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 二甲基亚砜：>20mg/mL |
| 形态 | 白色粉末 |
| 酸度系数(pKa) | 4.77±0.10(Predicted) |
| 颜色 | 米白色 |
| 稳定性 | 自购买之日起，稳定期为 1 年。 其DMSO 或乙醇溶液可在 -20°C 下保存长达 3 个月。 |
885101-89-3(GW9508) 用途与合成方法
pEC50: 7.32 (GPR40) and 5.46 (GPR120)
GW9508 stimulates intracellular Ca
2+
mobilization in HEK-293 cells expressing GPR40 (pEC
50
of 7.32) or GPR120 (pEC
50
of 5.46), but not in the parent HEK-293 cell line.
GW9508 produces a concentration-dependent increase (pEC
50
of 6.14) in glucose-stimulated insulin secretion at high glucose levels (25 mM). This resulted in a 1.52-fold increase in insulin secretion with 20 μM GW9508 in the presence of 25 mM glucose, compared with 25 mM glucose alone. The ability of GW9508 (10 μM) to enhance insulin secretion from MIN6 cells is significantly enhanced as glucose concentrations are increased.
GW9508 inhibits CCL17 and CCL5 expression in a pertussis toxin-sensitive manner. The inhibitory effect by GW9508 is abrogated by depletion of GPR40 with RNA interference. GW9508 further suppresses expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-α and IFN-γ. GW9508 also inhibits CCL5 and CXCL10 production by normal human epidermal keratinocytes.
Administration of GW9508 200 (μM) topically to the skin suppresses ear swelling in a repeated hapten application model (BALB/c and C57BL/6 mice) and contact hypersensitivity with downregulation of CCL5 and CXCL10, respectively.
885101-89-3(GW9508) 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-15589 | 5 mg | 312 | ||
| 2024-01-25 | HY-15589 | 885101-89-3(GW9508) | 885101-89-3 | 10mg | 500 |
